Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial) | MicrobiomeTrials← Back to trialsNCT07808333
Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2027-06-01Est. Completion: 2029-09-30
Enrollment target: 96 participants Locations- University of Chicago Medicine Duchossois Center for Advanced Medicine, Chicago, Illinois, United States
Other microbiome trials you might be interested in
Glaucoma
Open-angle glaucoma is the most common type of glaucoma, a disease that damages the nerves in the eye and can lead to vi…
Boston, United StatesEst. completion Jul 31, 2030
Glaucoma
Glaucoma is one of the leading causes of irreversible blindness worldwide. Early diagnosis is crucial to prevent vision …
Multiple LocationsEst. completion Nov 2027